Glycine propionyl-L-carnitine
US$ 21.24
glutathione for parkinson's disease 2020 Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation Revamping Parkinson's disease therapy using
Description
10.1124/jpet.104.078469 127 LeeE
Sharkey and O'Neill, 2019)
Examples include restricting CB 1 R agonists to peripheral receptors, creating specific CB 2 R agonists, inhibition of endocannabinoid metabolism or reuptake and modulating non-CB 1 R/CB 2 R targets of cannabinoids such as TRPV1, PPARs and GPR55 [127]
It also reveals activation of mitochondrial apoptosis pathways
They are effective and cause minimal side effects
